Inhibition of DNA methylation reverses norepinephrine-induced cardiac hypertrophy in rats

Daliao Xiao, Chiranjib Dasgupta, Man Chen, Kangling Zhang, John Buchholz, Zhice Xu, Lubo Zhang

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

AimsThe mechanisms of heart failure remain largely elusive. The present study determined a causative role of DNA methylation in norepinephrine-induced heart hypertrophy and reduced cardiac contractility.Methods and resultsMale adult rats were subjected to norepinephrine infusion for 28 days, some of which were treated with 5-aza-2′-deoxycytidine for the last 6 days of norepinephrine treatment. At the end of the treatment, hearts were isolated and left ventricular morphology and function as well as molecular assessments was determined. Animals receiving chronic norepinephrine infusion showed a sustained increase in blood pressure, heightened global genomic DNA methylation and changes in the expression of subsets of proteins in the left ventricle, left ventricular hypertrophy, and impaired contractility with an increase in the susceptibility to ischaemic injury. Treatment of animals with 5-aza-2′-deoxycytidine for the last 6 days of norepinephrine infusion reversed norepinephrine-induced hypermethylation, corrected protein expression patterns, and rescued the phenotype of heart hypertrophy and failure.ConclusionsThe findings provide novel evidence of a causative role of increased DNA methylation in programming of heart hypertrophy and reduced cardiac contractility, and suggest potential therapeutic targets of demethylation in the treatment of failing heart and ischaemic heart disease.

Original languageEnglish (US)
Pages (from-to)373-382
Number of pages10
JournalCardiovascular Research
Volume101
Issue number3
DOIs
StatePublished - Mar 1 2014
Externally publishedYes

Fingerprint

Cardiomegaly
DNA Methylation
Norepinephrine
decitabine
Heart Failure
Left Ventricular Hypertrophy
Left Ventricular Function
Heart Ventricles
Myocardial Ischemia
Proteins
Blood Pressure
Phenotype
Wounds and Injuries

Keywords

  • Failure
  • Heart
  • Hypertrophy
  • Methylation
  • Proteomic

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Physiology

Cite this

Inhibition of DNA methylation reverses norepinephrine-induced cardiac hypertrophy in rats. / Xiao, Daliao; Dasgupta, Chiranjib; Chen, Man; Zhang, Kangling; Buchholz, John; Xu, Zhice; Zhang, Lubo.

In: Cardiovascular Research, Vol. 101, No. 3, 01.03.2014, p. 373-382.

Research output: Contribution to journalArticle

Xiao, Daliao ; Dasgupta, Chiranjib ; Chen, Man ; Zhang, Kangling ; Buchholz, John ; Xu, Zhice ; Zhang, Lubo. / Inhibition of DNA methylation reverses norepinephrine-induced cardiac hypertrophy in rats. In: Cardiovascular Research. 2014 ; Vol. 101, No. 3. pp. 373-382.
@article{cedbc5752ae3430fa13231d2b0650cf2,
title = "Inhibition of DNA methylation reverses norepinephrine-induced cardiac hypertrophy in rats",
abstract = "AimsThe mechanisms of heart failure remain largely elusive. The present study determined a causative role of DNA methylation in norepinephrine-induced heart hypertrophy and reduced cardiac contractility.Methods and resultsMale adult rats were subjected to norepinephrine infusion for 28 days, some of which were treated with 5-aza-2′-deoxycytidine for the last 6 days of norepinephrine treatment. At the end of the treatment, hearts were isolated and left ventricular morphology and function as well as molecular assessments was determined. Animals receiving chronic norepinephrine infusion showed a sustained increase in blood pressure, heightened global genomic DNA methylation and changes in the expression of subsets of proteins in the left ventricle, left ventricular hypertrophy, and impaired contractility with an increase in the susceptibility to ischaemic injury. Treatment of animals with 5-aza-2′-deoxycytidine for the last 6 days of norepinephrine infusion reversed norepinephrine-induced hypermethylation, corrected protein expression patterns, and rescued the phenotype of heart hypertrophy and failure.ConclusionsThe findings provide novel evidence of a causative role of increased DNA methylation in programming of heart hypertrophy and reduced cardiac contractility, and suggest potential therapeutic targets of demethylation in the treatment of failing heart and ischaemic heart disease.",
keywords = "Failure, Heart, Hypertrophy, Methylation, Proteomic",
author = "Daliao Xiao and Chiranjib Dasgupta and Man Chen and Kangling Zhang and John Buchholz and Zhice Xu and Lubo Zhang",
year = "2014",
month = "3",
day = "1",
doi = "10.1093/cvr/cvt264",
language = "English (US)",
volume = "101",
pages = "373--382",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Inhibition of DNA methylation reverses norepinephrine-induced cardiac hypertrophy in rats

AU - Xiao, Daliao

AU - Dasgupta, Chiranjib

AU - Chen, Man

AU - Zhang, Kangling

AU - Buchholz, John

AU - Xu, Zhice

AU - Zhang, Lubo

PY - 2014/3/1

Y1 - 2014/3/1

N2 - AimsThe mechanisms of heart failure remain largely elusive. The present study determined a causative role of DNA methylation in norepinephrine-induced heart hypertrophy and reduced cardiac contractility.Methods and resultsMale adult rats were subjected to norepinephrine infusion for 28 days, some of which were treated with 5-aza-2′-deoxycytidine for the last 6 days of norepinephrine treatment. At the end of the treatment, hearts were isolated and left ventricular morphology and function as well as molecular assessments was determined. Animals receiving chronic norepinephrine infusion showed a sustained increase in blood pressure, heightened global genomic DNA methylation and changes in the expression of subsets of proteins in the left ventricle, left ventricular hypertrophy, and impaired contractility with an increase in the susceptibility to ischaemic injury. Treatment of animals with 5-aza-2′-deoxycytidine for the last 6 days of norepinephrine infusion reversed norepinephrine-induced hypermethylation, corrected protein expression patterns, and rescued the phenotype of heart hypertrophy and failure.ConclusionsThe findings provide novel evidence of a causative role of increased DNA methylation in programming of heart hypertrophy and reduced cardiac contractility, and suggest potential therapeutic targets of demethylation in the treatment of failing heart and ischaemic heart disease.

AB - AimsThe mechanisms of heart failure remain largely elusive. The present study determined a causative role of DNA methylation in norepinephrine-induced heart hypertrophy and reduced cardiac contractility.Methods and resultsMale adult rats were subjected to norepinephrine infusion for 28 days, some of which were treated with 5-aza-2′-deoxycytidine for the last 6 days of norepinephrine treatment. At the end of the treatment, hearts were isolated and left ventricular morphology and function as well as molecular assessments was determined. Animals receiving chronic norepinephrine infusion showed a sustained increase in blood pressure, heightened global genomic DNA methylation and changes in the expression of subsets of proteins in the left ventricle, left ventricular hypertrophy, and impaired contractility with an increase in the susceptibility to ischaemic injury. Treatment of animals with 5-aza-2′-deoxycytidine for the last 6 days of norepinephrine infusion reversed norepinephrine-induced hypermethylation, corrected protein expression patterns, and rescued the phenotype of heart hypertrophy and failure.ConclusionsThe findings provide novel evidence of a causative role of increased DNA methylation in programming of heart hypertrophy and reduced cardiac contractility, and suggest potential therapeutic targets of demethylation in the treatment of failing heart and ischaemic heart disease.

KW - Failure

KW - Heart

KW - Hypertrophy

KW - Methylation

KW - Proteomic

UR - http://www.scopus.com/inward/record.url?scp=84894518920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894518920&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvt264

DO - 10.1093/cvr/cvt264

M3 - Article

VL - 101

SP - 373

EP - 382

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 3

ER -